BioPharmSignal logoBioPharmSignal

Biotech News

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results

Neurocrine Biosciences (NBIX)Neurocrine BiosciencesEarnings

Conference Call and Webcast Scheduled for Monday, November 2 SAN DIEGO, Oct. 12, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its third quarter 2026 financial results conference call and webcast for 1:30 p.m. Pacific Time ( 4:30 p.m.

Related news

HRMYHarmony Biosciences2026-10-20 12:05 EST

Harmony Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026

XERSXeris Pharmaceuticals2026-10-22 12:00 EST

Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026

TEVATeva Pharmaceutical Industries2026-09-23 20:45 EST

Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET

VKTXViking Therapeutics2026-10-21 20:05 EST

Viking Therapeutics to Report Financial Results for Third Quarter 2026 on October 28, 2026

ALKSAlkermes plc2026-10-20 20:00 EST

Alkermes to Report Third Quarter Financial Results on November 3, 2026

ABOSAcumen Pharmaceuticals2026-10-19 20:00 EST

Acumen Pharmaceuticals to Report Third Quarter Financial Results on October 26, 2026

AXSMAxsome2026-10-07 11:00 EST

Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2

NBIXNeurocrine Biosciences2026-09-30 12:30 EST

Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference

NBIXNeurocrine Biosciences2026-08-12 12:30 EST

Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia

GANXGain Therapeutics2026-08-11 11:00 EST

Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update

View all latest news

Neurocrine Biosciences

Neuroscience and Endocrinology Portfolio Neurocrine Biosciences discovers, develops and commercializes medicines for neuropsychiatric, neurological, endocrine and immunological disorders. Its business combines several first-in-class commercial products with a deep mid- and late-stage pipeline. Commercial Medicines The portfolio includes...

Recent company news

NBIXNeurocrine Biosciences2026-10-22 20:05 EST

Neurocrine Biosciences Announces Publication in Orphanet Journal of Rare Diseases Advancing Understanding of Hyperphagia in Prader-Willi Syndrome

NBIXNeurocrine Biosciences2026-10-20 12:30 EST

Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-'567 in Adults with Alzheimer's Disease

NBIXNeurocrine Biosciences2026-10-16 12:30 EST

Neurocrine Biosciences Presents Real-World Evidence Mapping the Lifelong, Evolving Impact of Classic Congenital Adrenal Hyperplasia

NBIXNeurocrine Biosciences2026-10-12 20:01 EST

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results

NBIXNeurocrine Biosciences2026-09-30 12:30 EST

Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference

Stock data

Close
141.31 USD
Market cap
15.57B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States